Zealand Pharma's Petrelintide Shows 9.2% Weight Loss in Phase 2 Trial for Type 2 Diabetes
Event summary
- Petrelintide achieved up to 9.2% mean body weight reduction at week 28 vs. 2.0% with placebo in ZUPREME-2 trial.
- HbA1c reduction of up to 0.65% vs. 0.23% increase with placebo.
- Safety profile consistent with prior Phase 2 trial, with low discontinuation rates (1.9% vs. 1.7% placebo).
- Phase 3 program initiated with Roche, enrolling ~7,000 participants across three trials.
The big picture
Zealand Pharma's positive Phase 2 results for petrelintide reinforce the growing focus on amylin analogs for weight management in type 2 diabetes. The collaboration with Roche underscores the strategic importance of this asset in addressing unmet needs in metabolic health. The initiation of Phase 3 trials marks a critical step in validating petrelintide's potential as a first-choice therapy, competing in a market increasingly dominated by GLP-1 agonists.
What we're watching
- Clinical Validation
- Whether petrelintide's efficacy and safety profile can be replicated in larger Phase 3 trials.
- Regulatory Pathway
- The pace at which Zealand Pharma and Roche can advance petrelintide through regulatory approvals.
- Commercial Potential
- How petrelintide positions against existing and emerging weight management therapies in the type 2 diabetes space.
Related topics